Christian Prudhomme, director of the Tour de France, defended the independence of drug testing procedures during the race amid accusations of favoritism towards French riders. His remarks came as controversy emerged following a series of nighttime doping controls conducted last Sunday.
Prudhomme spoke at the start of stage 18 of the Tour, affirming that the International Testing Agency (ITA) operates without bias. He emphasized that the agency’s work is autonomous and that neither he nor the race organizers are informed about testing schedules in advance. “We fought to have an independent agency, and now we have one,” Prudhomme said, adding that he only learns about testing at the same time as the public or later.
The comments were prompted by criticism from Matej Mohoric, a rider for Bahrain Victorious, who suggested that French competitor Paul Seixas, a 19-year-old viewed as a promising domestic contender, was treated differently during the recent testing. In a Tuesday interview, Mohoric indicated that Seixas had not been subjected to the same nighttime testing as others, calling for equal treatment of all riders regardless of nationality.
The ITA, which is responsible for anti-doping controls during the Tour, reiterated its independence from French anti-doping authorities and from race officials. Prudhomme highlighted the importance of this autonomy, referencing the Union Cycliste Internationale’s (UCI) establishment of the ITA as a separate entity to conduct testing free from external influence.
Notably, race leader Tadej Pogacar and his rival Jonas Vingegaard—who later withdrew from the race—were tested at 5 a.m. and 2 a.m., respectively, last Sunday. The UCI described these late-night tests as “exceptional measures” implemented only in limited and justified cases, underscoring their unusual nature.
Prudhomme defended the ITA’s actions, stating, “The ITA is doing the job it’s paid to do,” reaffirming that the agency is fulfilling its mandate to maintain clean competition. The director’s defense reflects ongoing sensitivities around doping controls in the Tour de France, particularly in the context of ensuring fair and impartial treatment for all competitors.
